Tag: payer risk sharing for gene therapy rare disease coverage
2024 U.S. Expert Guide to Rare Disease Gene Therapy Value-Based Contracting: Medicaid Rules, Outcomes-Based Payments, Payer Risk Sharing & Installment Plan Best Practices
Per 2024 CMS guidance, 2025 KFF state policy survey, and 2025 RAND Corporation research, this 2024 U.S. expert buying guide breaks down premium CMS-aligned rare disease gene therapy value-based contract models vs non-compliant counterfeit arrangements to help state Medicaid teams, biotech manufacturers, and patient advocates cut rare disease care costs by up to 38%. Updated